PubRank

Laura Gribaldo

Author PubWeight™ 29.23‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 A modular approach to the ECVAM principles on test validity. Altern Lab Anim 2004 1.04
2 Meeting report: Validation of toxicogenomics-based test systems: ECVAM-ICCVAM/NICEATM considerations for regulatory use. Environ Health Perspect 2006 0.98
3 The principles of weight of evidence validation of test methods and testing strategies. The report and recommendations of ECVAM workshop 58. Altern Lab Anim 2006 0.97
4 Hematotoxicity testing by cell clonogenic assay in drug development and preclinical trials. Curr Pharm Des 2005 0.93
5 Microenvironmental control of malignancy exerted by RNASET2, a widely conserved extracellular RNase. Proc Natl Acad Sci U S A 2010 0.90
6 Arsenic induces telomerase expression and maintains telomere length in human cord blood cells. Toxicology 2009 0.89
7 miRNA expression profiling in a human stem cell-based model as a tool for developmental neurotoxicity testing. Cell Biol Toxicol 2013 0.88
8 Overcoming barriers to validation of non-animal partial replacement methods/Integrated Testing Strategies: the report of an EPAA-ECVAM workshop. Altern Lab Anim 2009 0.87
9 The key role of adult stem cells: therapeutic perspectives. Curr Med Res Opin 2006 0.87
10 Response of human cord blood cells to styrene exposure: evaluation of its effects on apoptosis and gene expression by genomic technology. Toxicology 2004 0.86
11 The assessment of repeated dose toxicity in vitro: a proposed approach. The report and recommendations of ECVAM workshop 56. Altern Lab Anim 2006 0.86
12 Points of reference in the validation process: the report and recommendations of ECVAM Workshop 66. Altern Lab Anim 2008 0.86
13 Whole genome analysis and microRNAs regulation in HepG2 cells exposed to cadmium. ALTEX 2012 0.85
14 ECVAM's response to the changing political environment for alternatives: consequences of the European Union chemicals and cosmetics policies. Altern Lab Anim 2003 0.85
15 Molecular signature induced by RNASET2, a tumor antagonizing gene, in ovarian cancer cells. Oncotarget 2011 0.85
16 Application of the modular approach to an in-house validation study of real-time PCR methods for the detection and serogroup determination of verocytotoxigenic Escherichia coli. Appl Environ Microbiol 2011 0.84
17 Optimisation of the post-validation process: the report and recommendations of ECVAM Workshop 67. Altern Lab Anim 2008 0.83
18 Assessment of an automated in vitro basal cytotoxicity test system based on metabolically-competent cells. Toxicol In Vitro 2012 0.83
19 Toxicity of inorganic arsenic and its metabolites on haematopoietic progenitors "in vitro": comparison between species and sexes. Toxicology 2008 0.82
20 Loss of function of Ribonuclease T2, an ancient and phylogenetically conserved RNase, plays a crucial role in ovarian tumorigenesis. Proc Natl Acad Sci U S A 2013 0.82
21 Strategies to replace in vivo acute systemic toxicity testing. The report and recommendations of ECVAM Workshop 50. Altern Lab Anim 2004 0.82
22 A mesenchymal stromal cell line resistant to paclitaxel that spontaneously differentiates into osteoblast-like cells. Cell Biol Toxicol 2010 0.81
23 ECVAM prevalidation study on in vitro cell transformation assays: general outline and conclusions of the study. Mutat Res 2011 0.80
24 Application of in vitro cell transformation assays in regulatory toxicology for pharmaceuticals, chemicals, food products and cosmetics. Mutat Res 2012 0.80
25 Barriers to validation: a report by the European Partnership fo Alternative Approaches to Animal Testing (EPAA) Working Group 5. Altern Lab Anim 2008 0.79
26 CD45+/CD133+ positive cells expanded from umbilical cord blood expressing PDX-1 and markers of pluripotency. Cell Biol Int 2010 0.78
27 ECVAM and new technologies for toxicity testing. Adv Exp Med Biol 2012 0.78
28 ECVAM prevalidation of three cell transformation assays. ALTEX 2011 0.78
29 Combined in utero and juvenile exposure of mice to arsenate and atrazine in drinking water modulates gene expression and clonogenicity of myeloid progenitors. Toxicol Lett 2008 0.77
30 A methylcellulose microculture assay for the in vitro assessment of drug toxicity on granulocyte/macrophage progenitors (CFU-GM). Altern Lab Anim 2004 0.77
31 In vitro tests for haematotoxicity: prediction of drug-induced myelosuppression by the CFU-GM assay. Altern Lab Anim 2002 0.76
32 Prevalidation of the rat CFU-GM assay for in vitro toxicology applications. Altern Lab Anim 2010 0.76
33 The Use of In Vitro Systems for Evaluating Immunotoxicity: The Report and Recommendations of an ECVAM Workshop. J Immunotoxicol 2005 0.76
34 New hepatocytes for toxicology? Trends Biotechnol 2004 0.76
35 Naphthalene exposure: effects on gene expression and proliferation in human cord blood cells. J Biochem Mol Toxicol 2003 0.76
36 Microbiological risk assessment in stem cell manipulation. Crit Rev Microbiol 2008 0.76
37 Scoring CFU-GM colonies in vitro by data fusion: a first account. Exp Hematol 2007 0.75
38 Perinatal health in the Danube region - New Birth cohort justified. Rev Environ Health 2016 0.75
39 Refinement and optimisation of the rat CFU-GM assay to incorporate the use of cryopreserved bone-marrow cells for in vitro toxicology applications. Altern Lab Anim 2009 0.75
40 Modulation of different stress pathways after styrene and styrene-7,8-oxide exposure in HepG2 cell line and normal human hepatocytes. J Appl Toxicol 2006 0.75
41 Refinement of the colony-forming unit-megakaryocyte (CFU-MK) assay for its application to pharmaco-toxicological testing. Toxicol In Vitro 2003 0.75
42 Gene and protein expressions in human cord blood cells after exposure to acrylonitrile. J Biochem Mol Toxicol 2005 0.75
43 Sensitivity of human cord blood cells to tetrachloroethylene: cellular and molecular endpoints. Arch Toxicol 2005 0.75